Scholarlink

<p>Nasal decongestants like xylometazoline are widely used in postoperative care following septoplasty, yet their effectiveness in improving healing outcomes remains unclear. This meta-analysis evaluates the impact of xylometazoline compared to normal saline on post-septoplasty outcomes, including bleeding, crusting, nasal obstruction, pain, and patient satisfaction.&#xa0;PubMed, Google scholar, Cochrane, Scopus, and Web of Science were searched for relevant articles. A systematic review and meta-analysis were conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing xylometazoline to normal saline in post-septoplasty patients were included. Data were extracted for key outcomes, including visual analog scale (VAS) scores for pain, crusting, and bleeding, as well as patient-reported nasal obstruction and satisfaction. Pooled effect sizes were calculated using random and fixed-effects models, and heterogeneity was assessed via I² statistics.&#xa0;Four RCTs (<i>n</i> = 338) met inclusion criteria. Meta-analysis demonstrated a significant reduction in bleeding (MD = −1.80; 95% CI −2.15, −1.45; <i>p</i> &lt; 0.00001) and crusting (MD = −1.89; 95% CI −4.05, 0.27; <i>p</i> = 0.09) in the xylometazoline group. Nasal obstruction also showed a trend toward improvement but was not statistically significant (<i>p</i> = 0.06). Pain scores did not differ significantly between groups (MD = 0.03; 95% CI −0.85, 0.92; <i>p</i> = 0.94). Heterogeneity was moderate to high (I² range: 36−98%).&#xa0;Xylometazoline use post-septoplasty significantly reduces postoperative bleeding and crusting, with a potential trend toward improved nasal obstruction. However, no significant effect on pain was observed. Given the moderate-to-high heterogeneity, further high-quality RCTs with standardized outcome measures are needed to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Effectiveness of Xylometazoline (0.1%) vs. Normal Saline (0.9%) Irrigation on Post-Septoplasty Healing: A Meta-Analysis of Randomized Trials

  • 期刊论文

  • 发表日期：

    2025年9月23日

查看全文
  • Abdur Rehman,
  • Muhammad Tehseen Ahmad,
  • Muhammad Shuaib Khan,
  • Namra Asif,
  • Maimoona Maheen,
  • Zainab Shahid,
  • Shahroz Ansar,
  • Syed Turab Haider,
  • Shahzaib Maqbool,
  • Haissan Iftikhar,
  • Hina Javed,
  • Muhammad Haris

摘要

Nasal decongestants like xylometazoline are widely used in postoperative care following septoplasty, yet their effectiveness in improving healing outcomes remains unclear. This meta-analysis evaluates the impact of xylometazoline compared to normal saline on post-septoplasty outcomes, including bleeding, crusting, nasal obstruction, pain, and patient satisfaction. PubMed, Google scholar, Cochrane, Scopus, and Web of Science were searched for relevant articles. A systematic review and meta-analysis were conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing xylometazoline to normal saline in post-septoplasty patients were included. Data were extracted for key outcomes, including visual analog scale (VAS) scores for pain, crusting, and bleeding, as well as patient-reported nasal obstruction and satisfaction. Pooled effect sizes were calculated using random and fixed-effects models, and heterogeneity was assessed via I² statistics. Four RCTs (n = 338) met inclusion criteria. Meta-analysis demonstrated a significant reduction in bleeding (MD = −1.80; 95% CI −2.15, −1.45; p < 0.00001) and crusting (MD = −1.89; 95% CI −4.05, 0.27; p = 0.09) in the xylometazoline group. Nasal obstruction also showed a trend toward improvement but was not statistically significant (p = 0.06). Pain scores did not differ significantly between groups (MD = 0.03; 95% CI −0.85, 0.92; p = 0.94). Heterogeneity was moderate to high (I² range: 36−98%). Xylometazoline use post-septoplasty significantly reduces postoperative bleeding and crusting, with a potential trend toward improved nasal obstruction. However, no significant effect on pain was observed. Given the moderate-to-high heterogeneity, further high-quality RCTs with standardized outcome measures are needed to confirm these findings.